PDBP
The National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP) was established in 2013 to accelerate the discovery of promising new diagnostic and progression biomarkers for Parkinson's diseasethrough integration of existing biomarker efforts and fostering or expanding collaborations between researchers in all sectors. PDBP supports a variety of research projects that contribute standardized clinical data and biospecimens for broad sharing.
Study Participants
PDBP includes more than 20 closed and ongoing observational and interventional studies of Parkinson's disease (PD), Parkinson's disease dementia (PDD), Dementia with Lewy Bodies/Lewy Body Dementia (DLB/LBD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal degeneration (CBD), and other parkinsonisms. PDBP also includes data and samples from large number of neurologically normal individuals, also known as healthy controls (HC). Many PDBP participants were followed for 5+ years, with visits conducted every 6-12 months.
Samples and data are available from more than 2500 individuals.
Available Data
All PDBP-supported studies are required to collect a standardized minimum data set, which includes validated instruments such as the UPDRS and MOCA. In addition, data generated from the PDBP samples are made available through the PDBP Data Management Resource (DMR).
CLINICAL: motor, non-motor (cognitive, neurobehavioral, neuropsychological, autonomic, sleep)
IMAGING: structural and fuctional neuroimaging (available for a subset of subjects)
BIOLOGIC: alpha-synuclein, amyloid-beta, tau (total and phosphorylated), unbiased proteomics and metabolomics, and more
GENETIC: whole genome sequencing, transcriptomics
Request access to the PDBP data through the DMR
Request access to the genetic data through AMP-PD
Available Biospecimens
DNA and RNA from blood, plasma, serum, whole blood, urine and CSF.